ライフサイエンスコーパス: morbid obesity

1 hepatic fibrosis in patients with severe to morbid obesity.

2 aused by hepatic pathology that results from morbid obesity.

3 ctive primary procedure for the treatment of morbid obesity.

4 on following gastric restrictive surgery for morbid obesity.

5 BPD) has been advocated for the treatment of morbid obesity.

6 tive procedure for the surgical treatment of morbid obesity.

7 and effective approach for the treatment of morbid obesity.

8 utations in the leptin receptor gene develop morbid obesity.

9 t mechanisms of cardiovascular protection in morbid obesity.

10 ]) for the classification of liver injury in morbid obesity.

11 tical eligibility criteria for patients with morbid obesity.

12 n increasingly popular form of treatment for morbid obesity.

13 astric bypass surgery-induced weight loss in morbid obesity.

14 routine coverage for SG for the treatment of morbid obesity.

15 c fat using 3T magnetic resonance imaging in morbid obesity.

16 nd db/db mice in the absence of diabetes and morbid obesity.

17 receptor-deficient (db/db) mice that develop morbid obesity.

18 ral tissue, but this capacity decreases with morbid obesity.

19 festyle changes alone in treating adolescent morbid obesity.

20 based on the complicating issues surrounding morbid obesity.

21 tes in patients who do not meet criteria for morbid obesity.

22 in 48 of 1282 patients (3.7%) after RYGB for morbid obesity.

23 , and may have implications for treatment of morbid obesity.

24 patients with gastric motility disorders or morbid obesity.

25 in the ob gene causes leptin deficiency and morbid obesity.

26 f death increased 7.4 times in patients with morbid obesity.

27 in 48 of 904 patients (5.3%) after RYGBP for morbid obesity.

28 a spectrum of NAFLD that may prelude NASH in morbid obesity.

29 Deficiency of either leptin or LRb causes morbid obesity.

30 fter gastric bypass surgery for treatment of morbid obesity.

31 ldhood obesity (P = 0.0003) and common adult morbid obesity (0.0003 < P < 0.007).

32 egion in 3q29; we designated this region the morbid obesity 1 (MO1) locus.

33 of overweight (39.8%), obesity (26.6%), and morbid obesity (3.6%) were similar in most geographic lo

34 of obstruction following gastric surgery for morbid obesity, 50% experienced relief of symptoms follo

35 Morbid obesity added 48 minutes to OT (P = 0.018), 1.1 u

36 Morbid obesity-adjusted rates of surgery were then calcu

37 Morbid obesity alters drug dose requirement and time cou

38 the prevalence and clinical implications of morbid obesity among patients undergoing PCI.

39 the prevalence and clinical implications of morbid obesity among patients undergoing percutaneous co

40 t effective method to curtail the effects of morbid obesity and all of its comorbid conditions.

41 iary protein CEP19 in humans and mice causes morbid obesity and defines a target for investigating th

42 tations of leptin or leptin receptor develop morbid obesity and diabetes.

43 re defective in leptin signaling and develop morbid obesity and diabetes.

44 ion of inflammation resolution prevents from morbid obesity and hyperglycemia under dietary overload

45 considered the most effective treatment for morbid obesity and its comorbidities; however, a systema

46 ective in the treatment of fully established morbid obesity and its endocrine and metabolic consequen

47 device may be suitable for the treatment of morbid obesity and its related comorbidities.

48 erformed in liver transplant recipients with morbid obesity and may lead to weight loss, correction o

49 f the most efficient procedures for treating morbid obesity and results in weight-loss and improvemen

50 is a reasonable choice for the treatment of morbid obesity and should be covered by both public and

51 at macrophages in WAT play an active role in morbid obesity and that macrophage-related inflammatory

52 (LAMB3) gene showing strong association with morbid obesity and thereby risk of type 2 diabetes.

53 rt were patients with a primary diagnosis of morbid obesity and who underwent laparoscopic Roux-en-Y

54 For type 2 diabetes, moderate and morbid obesity, and for both the Q121 and three-marker h

55 Baseline depressive symptoms, morbid obesity, and intensive care unit benzodiazepine d

56 sm, nonalcoholic steatohepatitis (NASH), and morbid obesity, and may contribute to liver disease.

57 nsity and angiogenic capacity decreased with morbid obesity, and subcutaneous, but not visceral, adip

58 Severe and morbid obesity are still relatively rare in France, with

59 epresent what we believe is a novel model of morbid obesity associated with an improved metabolic pro

60 rtension, congenital cyanotic heart disease, morbid obesity associated with sleep apnea syndrome, sic

61 Paradoxically, even morbid obesity associates with better outcomes in studie

62 switch as the primary surgical treatment of morbid obesity at a single institution during the 10-yea

63 ix of the remaining patients have persistent morbid obesity at least 2 years after surgery but refuse

64 ino acid changes, are null mutations causing morbid obesity, because homozygotes for the variant sequ

65 oux-en-Y gastric bypass for the treatment of morbid obesity between 1999 and 2002 (n = 24,166).

66 ry laparoscopic gastric bypass operation for morbid obesity between May 1, 2007, and September 30, 20

67 nfidence interval (CI): 1.14, 3.20), whereas morbid obesity (BMI >/= 40) was suggestive of increased

68 cant predictors of a wound complication were morbid obesity (BMI >30), having had a MT, low preoperat

69 rother had RP, PAP, mild mental retardation, morbid obesity (BMI >50 and 37, respectively), lobulated

70 BMI>31 indicates morbid obesity, BMI>27 indicates >20% over ideal body we

71 Morbid obesity (body mass index > or =40 kg/m(2)) is an

72 We examined the prevalence of morbid obesity (body mass index [BMI] >/= 40 kg/m(2)) am

73 nts who do not meet body weight criteria for morbid obesity (body mass index [BMI], <35 kg/m), but la

74 ic bypass is a highly successful approach to morbid obesity but results in significant perioperative

75 obese controls and accounted for 0.7% of our morbid obesity cases (body mass index (BMI) >or= 40 kg m

76 ass is the procedure of choice when GERD and morbid obesity coexist.

77 age points) also was observed in adults with morbid obesity compared with normal-weight controls.

78 The number of patients with obesity and morbid obesity continues to increase.

79 term (<2 years) efficacy of RYGB surgery for morbid obesity, corroborated by meta-analytic techniques

80 18-month-old female child who presented with morbid obesity, decreased linear growth, and reversal of

81 Leptin deficiency in mice and humans causes morbid obesity, diabetes, and various neuroendocrine ano

82 past year have focused on three broad areas: morbid obesity, gastric cancer, and peptic ulcer disease

83 ic gastric banding as a primary treatment of morbid obesity has been widely accepted, the effects of

84 Morbid obesity has no clinically significant impact on t

85 The prevalence of morbid obesity has risen sharply in recent years, even a

86 Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort.

87 The prevalence of obesity, and morbid obesity in particular, continues to rise rapidly

88 ght to evaluate the prognostic impact of pre-morbid obesity in patients with HF.

89 ency coding variant that was associated with morbid obesity in the LAMB3 gene.

90 shift in the type of procedure performed for morbid obesity in the United States toward sleeve gastre

91 d duodenal switch procedure as performed for morbid obesity involves a 75% subtotal greater curvature

92 Morbid obesity is a barrier to kidney transplantation du

93 Morbid obesity is a global health epidemic.

94 Morbid obesity is also associated with an increased risk

95 Morbid obesity is an epidemic in the United States and p

96 Morbid obesity is associated with higher mortality on th

97 Although the predisposition to morbid obesity is heritable, the identities of the disea

98 Morbid obesity is increasing in prevalence among patient

99 The number of bariatric interventions for morbid obesity is increasing worldwide.

100 Morbid obesity is increasingly becoming a major public h

101 frequently used and effective treatment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB

102 94 to 2003 was performed using the key words morbid obesity, laparoscopy, bariatric surgery, pneumope

103 The surgical treatment of morbid obesity leads to dramatic improvement in the como

104 Morbid obesity may be accompanied by diabetes and painfu

105 gn pathology (n = 48) and gastric bypass for morbid obesity (n = 40) were assessed.

106 Morbid obesity occurs frequently in patients with renal

107 and differing socio-cultural perceptions of morbid obesity on racial disparities.

108 though some individual offspring suffer from morbid obesity, others escape the malprogramming.

109 lated donor nephrectomy, gastric banding for morbid obesity, partial gastrectomy, and various other p

110 Morbid obesity predicted higher post-LT mortality before

111 pproximately 1% of eligible individuals with morbid obesity receive bariatric surgery.

112 P = 0.46 for type 2 diabetes, moderate, and morbid obesity, respectively).

113 elucidating the key networks associated with morbid obesity, response to RYGB, and disease as a whole

114 in leptin-deficient adults with established morbid obesity results in profound weight loss, increase

115 ed by infantile hypotonia, short stature and morbid obesity, results from deficiencies in multiple ge

116 As the number of people with morbid obesity rises, so will the number of bariatric pr

117 In addition, morbid obesity's impact on many organ systems decreases

118 This phenotype closely resembles the morbid obesity seen in humans.

119 Roux-en-Y gastric bypass, in the Adolescent Morbid Obesity Surgery (AMOS) study.

120 Here, we describe an autosomal-recessive morbid-obesity syndrome and identify the disease-causing

121 th null mutations in a single gene producing morbid obesity, the new models develop a more moderate o

122 Among patients with morbid obesity, the use of vagal nerve block therapy com

123 Medline search using "perioperative care," "morbid obesity," "thromboembolic complications," "preope

124 adhere to practice guidelines that consider morbid obesity to be a contraindication to liver transpl

125 cantly lower in morbidly obese patients, and morbid obesity was an independent predictor of mortality

126 A NASH Clinical Scoring System for Morbid Obesity was derived to predict the probability of

127 sence of 5 conditions commonly comorbid with morbid obesity were examined for morbidly obese patients

128 The relationship of morbid obesity with LT outcomes and survival benefit in